BloggingStocks

Analyst upgrades, downgrades and initiations: DOLE, DWA, ESRX, FOSL, GIL, HR, STZ ...

Eric Buscemi — Wed, 02 Dec 2009 11:40:00 EST

Analyst Upgrades

Janney Montgomery upgraded Dreamworks (DWA) to buy from neutral on valuation and believes Dragon will be a major hit. The firm has a $45 target on the stock.
Thomas Weisel upgraded Gildan Activewear (GIL) to market weight from underweight, citing expectations for increased market shares in the U.S. screen print channel. The firm raised its target to $17 from $12.
P.F. Chang's (PFCB) was upgraded to overweight from equal weight at Morgan Stanley.
PEPCO Holdings (POM) was upgraded to outperform from neutral at Credit Suisse.
Arris (ARRS) was upgraded to buy from neutral at UBS.

Eric Buscemi — Wed, 25 Mar 2009 11:30:00 EST

Analyst upgrades:

JMP Securities upgraded CB Richard Ellis (NYSE: CBG) to Outperform from Market Perform. The analyst believes the new Public-Private Investment Program will create liquidity, which will result in some degree of activity. Shares were also upgraded at JP Morgan to Overweight from Neutral.
Thomas Weisel upgraded Linear Tech (NASDAQ: LLTC) to Overweight from Market Weight due to stabilizing business and favorable end market exposure.
UBS upgraded PepsiCo (NYSE: PEP) to Buy from Neutral and raised its target to $60 from $57 due to moderating input costs, earnings and investment flexibility, improving U.S. beverage business, and leverage from its market share in food.
Tibco (NASDAQ: TIBX) was raised to Buy from Neutral at Goldman.
Philips Electronics (NYSE: PHG) was upgraded at ING Group to Buy from Hold.
Hospira (NYSE: HSP) was upgraded to Outperform from Market Perform at Leerink.

Eric Buscemi — Thu, 29 May 2008 11:16:00 EST

MOST NOTEWORTHY: Beckman Coulter, BT Group and Micromet were today's noteworthy initiations:

Oppenheimer believes Beckman Coulter (NYSE:BEC) is well-positioned to leverage its broad installed base in the clinical lab market to increase sales of its consumable and a new molecular diagnostics instrument expected in 2010. The firm initiated shares with an Outperform rating and $80 target.
Societe Generale expects BT Group's (NYSE:BT) domestic revenues to deteriorate as line erosion accelerates; shares were assumed with a Sell rating.
Roth Capital started Micromet (NASDAQ:MITI) with a Buy rating and $3 target. The firm expects the company's proprietary 'BiTE' antibody platform to gain validation as its lead candidate MT103 starts accumulating clinical data in multiple hematology indications.

OTHER INITIATIONS:

Yahoo! (NASDAQ:YHOO) was initiated with a Neutral rating at Merrill.
Piper resumed coverage of Alexion Pharma (NASDAQ:ALXN) with a Buy rating and $88 target.
MedAssets (NASDAQ:MDAS) was started at Jefferies with a Buy rating and $25 target.

Analyst initiations: BEC, BT and MITI originally appeared on BloggingStocks on Thu, 29 May 2008 11:16:00 EST. Please see our terms for use of feeds.

Eric Buscemi — Thu, 20 Mar 2008 10:52:00 EST

MOST NOTEWORTHY: Abbott Lab, Fannie Mae, Freddie Mac and Micromet were today's noteworthy upgrades:

Wachovia upgraded Abbott Lab (NYSE: ABT) to Outperform from Market Perform as they believe their earlier concerns have been addressed. Past concerns included the potential for a negative outcome from the FDA panel on Xience and slowing prescription growth of lead drug Humira.
Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE) were raised to Outperform from Market Perform at Keefe Bruyette citing recent government actions to stabilize the mortgage markets.
Micromet (NASDAQ: MITI) was upgraded at RBC Capital to Outperform from Sector Perform as they expect positive data for its lead candidate, MT103, by year-end.

OTHER UPGRADES: